Last updated: February 14, 2026
What is the current market status of the drug NDC 00555-0071?
NDC 00555-0071 corresponds to Xyrem (sodium oxybate), used primarily for narcolepsy with cataplexy and sleep paralysis. It has a high prescription volume due to its specific indication and restricted distribution because of abuse potential and regulatory controls.
What is the current pricing structure for Xyrem?
Xyrem’s wholesale acquisition cost (WAC) for a typical 60 mL bottle (10 g/30 mL) is approximately $1,250. The average wholesale price (AWP) is approximately $1,400, with suggested retail prices reaching nearly $1,500. The per-gram cost is near $125.
| Price Metric |
Approximate Value |
| WAC per 60 mL bottle |
$1,250 |
| AWP per 60 mL bottle |
$1,400 |
| Retail per 60 mL bottle |
$1,500 |
| Cost per gram |
$125 |
Pricing varies based on insurer contracts, pharmacy discounts, and patient assistance programs.
How does demand influence market dynamics?
Market demand for Xyrem remains stable with approximately 10,000 to 15,000 prescriptions annually in the U.S. (IQVIA data, 2022). The drug’s restricted formulary status limits supply dynamics but sustains high prices due to its narrow indication and regulatory restrictions.
Drug shortages have rarely occurred, but regulatory scrutiny impacts supply chain logistics, potentially leading to short-term pricing fluctuations.
What are the key factors shaping future price projections?
Regulatory and Reimbursement Policies
- The FDA maintains a REMS (Risk Evaluation and Mitigation Strategy) program for Xyrem, restricting distribution to certified pharmacies and specialty providers.
- Insurance coverage is prevalent but often involves prior authorization and high copayments, impacting net revenue.
Patent and Market Exclusivity
- The core patent for Xyrem expired in 2017. However, the manufacturer maintains exclusivity through patent extensions and formulation protections until 2027.
- Generic formulations are not available as of early 2023 due to patent litigations and regulatory hurdles.
Competition and Biosimilar Entry
- No biosimilars or generics are authorized currently, sustaining high prices.
- Future entry may depend on patent rulings and legal challenges, which could influence pricing downwards.
Market Expansion Potential
- Xyrem’s approval for additional indications, such as idiopathic hypersomnia, could expand the patient base marginally.
- Off-label use remains rare due to legal and safety considerations.
Cost-Containment Measures
- Payers may implement stricter formularies or negotiate discounts, which could reduce manufacturer revenue.
- Biosimilar or alternative therapies could emerge, pressuring Xyrem’s pricing in the long term.
What are the projected price trends for Xyrem?
Short to Mid-Term (next 2-3 years)
- Prices are expected to remain stable barring significant legal rulings or market entry of generics.
- Price erosion could occur if generic equivalents penetrate the market, potentially reducing prices by 20-30% within 3-5 years post-patent expiration, akin to trends seen with other high-cost specialty drugs.
Long-Term (beyond 5 years)
- Patent protections may expire around 2027, with generic competition likely thereafter.
- Biosimilar or alternative treatment options could depress pricing further; however, complex formulation and safety profile slow down immediate generic entry.
Market Volume and Revenue Projections
- Estimated annual revenue for the drug exceeds $400 million in the U.S., based on volume and pricing.
- Market volume is projected to decline slightly due to increasing competition and potential regulatory price controls, but total revenue may stabilize if new indications are approved.
What are the competitive alternatives?
- There are no direct biosimilar competitors as of 2023.
- Other wakefulness and sleep disorder medications, such as modafinil or sodium oxybate formulations, serve similar patient populations but differ in delivery and approval status.
- Future generics or new molecular entities could impact the landscape.
Summary
Xyrem's market remains high-priced due to regulatory protections, lack of generic competition, and its niche application. Expect stability in pricing in the short term, with potential for significant price reduction following patent expirations and market entry of biosimilars, anticipated around 2027. Demand is steady, primarily limited by indication scope and regulatory restrictions, supporting high revenue levels for the near future.
Key Takeaways
- Current price of approximately $125 per gram.
- Market volume: around 10,000-15,000 prescriptions annually.
- Patent expiry expected in 2027 opens the pathway for generics.
- No biosimilars in circulation, maintaining high exclusivity.
- Future pricing will be influenced heavily by patent litigation outcomes and market entry of generics.
FAQs
Q1: When will generic versions of Xyrem become available?
Patent protections are expected to expire around 2027, after which generics may emerge, pending legal and regulatory approvals.
Q2: How does insurance impact Xyrem’s price?
Insurance plans often negotiate discounts, and patients may face high co-pays or prior authorization requirements, influencing out-of-pocket costs.
Q3: Could new indications affect the market size?
Yes, if approved for additional conditions, demand could increase, supporting stable or higher pricing temporarily.
Q4: What regulatory issues could influence future prices?
FDA REMS restrictions limit distribution, and any modifications to these policies could affect supply and pricing.
Q5: Are there alternative therapies for narcolepsy?
Yes, drugs such as modafinil or armodafinil are alternatives, but none match sodium oxybate’s efficacy in controlling cataplexy.
References:
- IQVIA. (2022). Pharmaceutical Market Data Reports.
- FDA. (2023). Xyrem REMS Program.
- GoodRx. (2023). Xyrem Pricing Overview.
